POSA117 Cost-Effectiveness Analysis of Third-Line Pazopanib Versus Regorafenib for Metastatic or Unresectable Gastrointestinal Stromal Tumors in China

Abstract

Authors

M Rui YC Wang YD Cao Z Fei HC Li

Full Text Cite This Article
Back to ISPOR Europe 2021 Abstracts: Emerging Frontiers and Opportunities
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×